Small CapsOptiscan Imaging Moves Closer to Regulatory Clearance of Real-Time Surgical Imaging Platform
Optiscan Imaging submits InVue for FDA 510(k) review, moving its real-time surgical imaging platform closer to US clearance and commercialisation.
OIL
Health Care Equipment & Services
Optiscan Imaging
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 1 Dec 2025
- Reported shorts
- 12.5K
- Shares on issue
- 1.044B
Optiscan Imaging (OIL) News
Latest articles and price-sensitive announcements with AI sentiment classification.
StockheadLong Shortz with Optiscan: InVue reaches major US FDA milestone
US FDA 510(k) submission for InVue, OIL's flagship real-time point-of-care digital surgical microscope, is major milestone. ... Read More The post Long Shortz with Optiscan: InVue reaches major US FDA milestone appeared first on Stockhead.
Optiscan’s InVue surgery imaging tech heads to US FDA
The submission comes just days after OIL lodged a separate 510(k) application for its InForm digital pathology device on October ... Read More The post Optiscan’s InVue surgery imaging tech heads to US FDA appeared first on Stockhead.
ASXOptiscan Lodges U.S. FDA 510(k) Submission for InVue
other announcement
Long Shortz Optiscan: FDA submission opens path to US commercialisation
US FDA 510(k) submission for InForm digital pathology device is a major milestone towards potential US commercialisation. ... Read More The post Long Shortz Optiscan: FDA submission opens path to US commercialisation appeared first on Stockhead.
Optiscan’s digital pathology tech hits major US FDA milestone
The submission takes InForm beyond internal development, testing and validation and into the FDA’s formal regulatory assessment process. ... Read More The post Optiscan’s digital pathology tech hits major US FDA milestone appeared first on Stockhead.
Optiscan Lodges U.S. FDA 510(k) Submission for InForm
other announcement
KalkineWhy Is Optiscan Imaging (ASX:OIL) Listing New Employee Incentive Shares?
Highlights Optiscan Imaging (ASX:OIL) has applied to quote a modest tranche of previously granted employee incentive shares These shares are becoming tradeable now that their transfer restrictions have ceased The move reflects the company's continued use of equity incentives to align staff and shareholder interests Optiscan Imaging (ASX:OIL) has applied for quotation of a modest tranche of ordinary fully paid shares on the ASX, previously granted under an employee incentive scheme. Within the ...
Change of Director's Interest Notice
director_dealing announcement
Notification of cessation of securities - OIL
other announcement
Application for quotation of securities - OIL
other announcement
Google NewsASX Healthcare Spotlight: Could Optiscan Imaging (ASX:OIL) Be a September 2026 Stock to Watch? - Kalkine
ASX Healthcare Spotlight: Could Optiscan Imaging (ASX:OIL) Be a September 2026 Stock to Watch? Kalkine
Long Shortz with Optiscan: Digital pathology study passes 80-patient milestone
The company’s ACL digital pathology study reaches milestone with more than 80 patients now imaged using the InForm platform. ... Read More The post Long Shortz with Optiscan: Digital pathology study passes 80-patient milestone appeared first on Stockhead.
Optiscan hits 80-case imaging milestone in digital pathology study
The study is evaluating InForm in Australian Clinical Labs’ flagship anatomical pathology laboratory enabling ASX:OIL to assess its technology under ... Read More The post Optiscan hits 80-case imaging milestone in digital pathology study appeared first on Stockhead.
Optiscan Imaging Advances InForm Device with Digital Pathology Study
Optiscan Imaging advances ACL study, >80 cases imaged with InForm slide-free digital pathology, accelerating clinical validation and rollout.
Significant Milestone Reached in ACL Digital Pathology Study
other announcement
Change of Director's Interest Notice
director_dealing announcement
Application for quotation of securities - OIL
other announcement
Application for quotation of securities - OIL
other announcement
Change of Director's Interest Notice
director_dealing announcement
Change of Director's Interest Notice
director_dealing announcement
StockTake: Optiscan starts head and neck cancer study
The 35-patient study is part of Optiscan’s ongoing clinical collaboration with Mayo Clinic Rochester, with patient recruitment underway. ... Read More The post StockTake: Optiscan starts head and neck cancer study appeared first on Stockhead.
Optiscan Initiates Head and Neck Cancer Study in the US
other announcement
Is Optiscan Imaging (ASX:OIL) Sharpening Its Governance Framework?
Highlights Optiscan Imaging Limited (ASX:OIL) has lodged its FY2026 Corporate Governance Statement and Appendix 4G with the ASX. The framework covers board responsibilities, director appointment checks and direct accountability of the company secretary. The disclosure provides greater governance transparency as Optiscan develops advanced optical imaging technology for healthcare applications. Optiscan Imaging Limited (ASX:OIL) has formalised its latest corporate governance disclosures, giving ...
Companies Like Optiscan Imaging (ASX:OIL) Are In A Position To Invest In Growth - simplywall.st
Companies Like Optiscan Imaging (ASX:OIL) Are In A Position To Invest In Growth simplywall.st
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Roto-Gro International (ASX:OIL) Eases as Small-Cap Energy Stock Reflects Weaker Sector - Kalkine
Roto-Gro International (ASX:OIL) Eases as Small-Cap Energy Stock Reflects Weaker Sector Kalkine
Long Shortz with Optiscan Imaging: Breast cancer study begins
Dr Farah explains how its InVue and InForm technologies could improve surgical outcomes and the path to FDA submissions. ... Read More The post Long Shortz with Optiscan Imaging: Breast cancer study begins appeared first on Stockhead.
Long Shortz with Optiscan Imaging: Head and neck study accelerates
Why is this study an important milestone for Optiscan as it progresses FDA submissions for InForm and InVue. ... Read More The post Long Shortz with Optiscan Imaging: Head and neck study accelerates appeared first on Stockhead.
Optiscan to start new US breast cancer imaging study
The Mayo clinic study will evaluate Optiscans InVue and InForm devices in 35 US patients undergoing breast conserving surgery ... Read More The post Optiscan to start new US breast cancer imaging study appeared first on Stockhead.
Optiscan Signs New Research Agreement for Breast Study
other announcement
Optiscan takes head and neck cancer imaging study to live surgical phase ahead of schedule
The quicker-than-expected transition is set to provide time and cost efficiency benefits, while enabling expansion in the range of tissues ... Read More The post Optiscan takes head and neck cancer imaging study to live surgical phase ahead of schedule appeared first on Stockhead.
Health Check: No ‘burnt toast’ excuses as Optiscan trial runs ahead of schedule
Optiscan's first-in-human head and neck cancer imaging study has entered stage two ahead of time. The next stop is FDA ... Read More The post Health Check: No ‘burnt toast’ excuses as Optiscan trial runs ahead of schedule appeared first on Stockhead.
Head and Neck Study Progressing Ahead of Schedule
other announcement
Can Optiscan (ASX:OIL) Turn a First Launch Into Real Revenue?
Highlights Optiscan has launched its first clinical imaging device in the United States, a milestone that shifts it from developer to commercial player. The debut targets the veterinary market as a beachhead ahead of broader human clinical ambitions. The move lands during a broad rebound in Australian healthcare shares from recent multi-year lows. Optiscan Imaging (ASX:OIL), the Melbourne-based developer of miniaturised microscope technology that lets clinicians view ...
Long Shortz with Optiscan: InSpecta launches in the US vet market
The US launch of the InSpecta veterinary imaging device is a major commercial opportunity in the veterinary market. ... Read More The post Long Shortz with Optiscan: InSpecta launches in the US vet market appeared first on Stockhead.
Optiscan launches InSpecta device in US veterinary market
This marks a transition from technology and product developer to a commercial enterprise, while establishing a regulatory and commercial path ... Read More The post Optiscan launches InSpecta device in US veterinary market appeared first on Stockhead.
Optiscan Launches InSpecta Device for Veterinary Medicine
other announcement
Biocurious: Silence is golden as Optiscan targets the US veterinarian market
Optiscan expects the US FDA to clear its Inspecta veterinary imaging device – but only anticipates hearing from the agency ... Read More The post Biocurious: Silence is golden as Optiscan targets the US veterinarian market appeared first on Stockhead.
Optiscan reaches halfway mark in breast cancer imaging study
Optiscan Imaging reaches halfway mark in its first in-human breast cancer imaging study at The Royal Melbourne Hospital with 25 ... Read More The post Optiscan reaches halfway mark in breast cancer imaging study appeared first on Stockhead.
Halfway Mark Reached in Optiscan Breast Cancer Study
other announcement
Long Shortz with Optiscan Imaging: Advancing robotic surgery with Mayo Clinic
Optiscan Imaging reaches the 2 year milestone in its robotic surgery collaboration with the Mayo Clinic. ... Read More The post Long Shortz with Optiscan Imaging: Advancing robotic surgery with Mayo Clinic appeared first on Stockhead.
Optiscan marks Mayo Clinic milestone as robotic surgery collaboration progresses
Optiscan Imaging and Mayo Clinic have completed key development milestones under their robotic surgery imaging collaboration, with the agreement extended ... Read More The post Optiscan marks Mayo Clinic milestone as robotic surgery collaboration progresses appeared first on Stockhead.
Second Anniversary of Optiscan and Mayo Clinic Agreement
other announcement
Non-Executive Director Ronnie Song Sold A Bunch Of Shares In Optiscan Imaging - simplywall.st
Non-Executive Director Ronnie Song Sold A Bunch Of Shares In Optiscan Imaging simplywall.st
Change of Director's Interest Notice x4
director_dealing announcement